The InRange Study
Prof. Rich Bergenstal, endocrinologist and executive director of international Diabetes Center at Health Partners, Minneapolis, presenting glucose variability with second-generation basal insulin analogs Glargine 300 U/ml and Degludec 100 U/ml evaluated by CGM in people with T1DM based on the InRange randomized controlled trial.
![105-LB_ADA 2022_InRange_eposter with video_01](/.imaging/webp/sanofi-templates/w1080-16-9/dam/campus-sanofi-kw/new/science/image---2023-10-04T215528.234.jpg/jcr:content/image%20-%202023-10-04T215528.234.jpg)
105-LB_ADA 2022_InRange_eposter with video_01
Related articles
MAT-BH-2200730/V1/Sep2022